Alvotech Company Leadership
| ALVO Stock | USD 8.93 0.26 2.83% |
Alvotech employs about 1 K people. The company is managed by 18 executives with a total tenure of roughly 2362 years, averaging almost 131.0 years of service per executive, having 56.22 employees per reported executive. Analysis of Alvotech's management performance can provide insight into the firm performance.
Alvotech Management Team Effectiveness
The company has return on total asset (ROA) of 0.0702 % which means that it generated a profit of $0.0702 on every $100 spent on assets. This is way below average. Alvotech's management efficiency ratios could be used to measure how well Alvotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 5th of July 2025, Non Currrent Assets Other is likely to grow to about 27.7 M, while Total Assets are likely to drop about 895.9 M.As of the 5th of July 2025, Common Stock Shares Outstanding is likely to drop to about 183.2 M. In addition to that, Net Loss is likely to grow to about (439.1 M)
Alvotech Workforce Comparison
Alvotech is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 149,970. Alvotech maintains roughly 1,012 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08. Alvotech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Alvotech Price Series Summation is a cross summation of Alvotech price series and its benchmark/peer.
Alvotech Notable Stakeholders
An Alvotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alvotech often face trade-offs trying to please all of them. Alvotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alvotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Faysal Kalmoua | COO Director | Profile | |
| Benedikt Stefansson | VP Communications | Profile | |
| Christina Siniscalchi | Interim Officer | Profile | |
| Ming Li | Chief Officer | Profile | |
| Sandra Casaca | Chief Officer | Profile | |
| RoseMarie Ohlsson | Chief Officer | Profile | |
| Anil Okay | Chief Officer | Profile | |
| Giedrius Zunda | Chief Officer | Profile | |
| Sean Gaskell | Chief Officer | Profile | |
| Joel Morales | Chief Officer | Profile | |
| Joseph McClellan | Chief Officer | Profile | |
| Eva Gunnlaugsdottir | Vice Culture | Profile | |
| Tanya Zharov | General Counsel | Profile | |
| Mark Levick | Chief Officer | Profile | |
| Sigridur Gudlaugsdottir | VP HR | Profile | |
| Jenny Steingrimsdottir | Vice Culture | Profile | |
| Robert Wessman | Founder Directors | Profile | |
| Anthony III | Chief Officer | Profile |
About Alvotech Management Performance
The success or failure of an entity such as Alvotech often depends on how effective the management is. Alvotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alvotech management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alvotech management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. The company was founded in 2013 and is headquartered in Reykjavik, Iceland. Alvotech is traded on NASDAQ Exchange in the United States.
Alvotech Workforce Analysis
Traditionally, organizations such as Alvotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alvotech within its industry.Alvotech Manpower Efficiency
Return on Alvotech Manpower
| Revenue Per Employee | 483.9K | |
| Revenue Per Executive | 27.2M | |
| Net Loss Per Employee | 229.1K | |
| Net Loss Per Executive | 12.9M | |
| Working Capital Per Employee | 258.5K | |
| Working Capital Per Executive | 14.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alvotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Alvotech Stock, please use our How to Invest in Alvotech guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alvotech. If investors know Alvotech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alvotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share 0.37 | Revenue Per Share 2.124 | Quarterly Revenue Growth 2.6 | Return On Assets 0.0702 |
The market value of Alvotech is measured differently than its book value, which is the value of Alvotech that is recorded on the company's balance sheet. Investors also form their own opinion of Alvotech's value that differs from its market value or its book value, called intrinsic value, which is Alvotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alvotech's market value can be influenced by many factors that don't directly affect Alvotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alvotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alvotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alvotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.